Skip to content
Study details
Enrolling now

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Perspective Therapeutics
NCT IDNCT06710756ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1/2

Target enrollment

112

Study length

about 7.1 years

Ages

18–90

Locations

3 sites in MO, NE, PA

What this study is about

This trial is testing a new treatment called Lead-212 PSV359 in people with solid tumors. The goal is to determine the safety and effectiveness of this treatment.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take [203Pb]Pb-PSV359
  • 2.Take [212Pb]Pb-PSV359

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Primary: Determination of safety and tolerability of [203Pb]Pb-PSV359, Determination of safety and tolerability of [212Pb]Pb-PSV359

Secondary: Determination of duration of response following treatment with [212Pb]Pb-PSV359, Determination of pharmacokinetic properties of [203Pb]Pb-PSV359 and [212Pb]Pb-PSV359, Determination of progression free survival following treatment with [212Pb]Pb-PSV359

Body systems

Oncology